IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Chinese skepticism surrounding Western medicine's effectiveness has led to the rising popularity of traditional Chinese medicine, which is considered to be less toxic and to have fewer side effects. Patients are increasingly choosing traditional Chinese medicine as their primary medicinal treatment. Additionally, China's aging population and rising health consciousness are contributing to higher industry demand.Along with the Healthy China strategy, medical and healthcare system reforms have continued. The Traditional Chinese Medicine Manufacturing industry's revenue is expected to increase an annualized 8.0% over the five years through 2025. Industry revenue has recovered since the COVID-19 pandemic outbreak, and is expected to increase 5.0% in 2025, to $41.0 billion.Traditional Chinese medicine pills are the main product used in traditional Chinese medicine clinics and are also important components of Chinese patent drugs. The top four industry participants, TongRenTang, China TCM, Kangmei, and Taloph, account for a combined share of 10.0% of total industry revenue in 2025, indicating low market share concentration. The industry includes many small-scale enterprises. As the industry matures, some smaller companies will likely struggle to remain viable, and more competitive manufacturers will gain an increasing market share, pushing up concentration.The Chinese Government has strongly focused on the Traditional Chinese Medicine Manufacturing industry, and will continue to issue standards and specifications to increase its global competitiveness. Industry revenue is forecast to grow an annualized 5.0% over the five years through 2030, to total $52.2 billion.
Answer any industry question in minutes with our entire database at your fingertips.
Feed trusted, human-driven industry intelligence straight into your platform.
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
IBISWorld's research coverage on the Traditional Chinese Medicine Manufacturing industry in China includes market sizing, forecasting, data and analysis from 2015-2030. The most recent publication was released May 2025.
The Traditional Chinese Medicine Manufacturing industry in China operates under the industry code 2730. The Traditional Chinese Medicine Manufacturing industry in China produces herbal, animal-based and mineral-based Chinese medicine and extracts. Related terms covered in the Traditional Chinese Medicine Manufacturing industry in China include gmp (good manufacturing practice), otc (over the counter), good selling practice (gsp) and concentrated tcm granules.
Products and services covered in Traditional Chinese Medicine Manufacturing industry in China include Herbal traditional Chinese medicine, Animal-based traditional Chinese medicine and Mineral-based traditional Chinese medicine .
Companies covered in the Traditional Chinese Medicine Manufacturing industry in China include Beijing TongRenTang Co., Ltd., China Traditional Chinese Medicine Holdings Co., Ltd. and Kangmei Pharmaceutical Co., Ltd.
The Performance chapter covers detailed analysis, datasets, detailed current performance, sources of volatility and an outlook with forecasts for the Traditional Chinese Medicine Manufacturing industry in China.
Questions answered in this chapter include what's driving current industry performance, what influences industry volatility, how do successful businesses overcome volatility, what's driving the industry outlook. This analysis is supported with data and statistics on industry revenues, costs, profits, businesses and employees.
The Products and Markets chapter covers detailed product and service segmentation, analysis of major markets and international trade data for the for the Traditional Chinese Medicine Manufacturing industry in China.
Questions answered in this chapter include how are the industry's products and services performing, what are innovations in industry products and services, what products or services do successful businesses offer and what's influencing demand from the industry's markets. This includes data and statistics on industry revenues by product and service segmentation and major markets.
The Geographic Breakdown chapter covers detailed analysis and datasets on regional performance of the Traditional Chinese Medicine Manufacturing industry in China.
Questions answered in this chapter include where are industry businesses located and how do businesses use location to their advantage. This includes data and statistics on industry revenues by location.
The Competitive Forces chapter covers the concentration, barriers to entry and supplier and buyer profiles in the Traditional Chinese Medicine Manufacturing industry in China. This includes data and statistics on industry market share concentration, barriers to entry, substitute products and buyer & supplier power.
Questions answered in this chapter include what impacts the industry's market share concentration, how do successful businesses handle concentration, what challenges do potential industry entrants face, how can potential entrants overcome barriers to entry, what are substitutes for industry services, how do successful businesses compete with substitutes and what power do buyers and suppliers have over the industry and how do successful businesses manage buyer & supplier power.
The Companies chapter covers Key Takeaways, Market Share and Companies in the Traditional Chinese Medicine Manufacturing industry in China. This includes data and analysis on companies operating in the industry that hold a market share greater than 5%.
Questions answered in this chapter include what companies have a meaningful market share and how each company is performing.
The External Environment chapter covers Key Takeaways, External Drivers, Regulation & Policy and Assistance in the Traditional Chinese Medicine Manufacturing industry in China. This includes data and statistics on factors impacting industry revenue such as economic indicators, regulation, policy and assistance programs.
Questions answered in this chapter include what demographic and macroeconomic factors impact the industry, what regulations impact the industry, what assistance is available to this industry.
The Financial Benchmarks chapter covers Key Takeaways, Cost Structure, Financial Ratios, Valuation Multiples and Key Ratios in the Traditional Chinese Medicine Manufacturing industry in China. This includes financial data and statistics on industry performance including key cost inputs, profitability, key financial ratios and enterprise value multiples.
Questions answered in this chapter include what trends impact industry costs and how financial ratios have changed overtime.
The Industry Data chapter includes 10 years of historical data with 5 years of forecast data covering statistics like revenue, industry value add, establishments, enterprises, employment and wages in the Traditional Chinese Medicine Manufacturing industry in China.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
The market size of the Traditional Chinese Medicine Manufacturing industry in China is $41.0bn in 2026.
There are 1,533 businesses in the Traditional Chinese Medicine Manufacturing industry in China, which has grown at a CAGR of 2.0 % between 2020 and 2025.
The Traditional Chinese Medicine Manufacturing industry in China is unlikely to be materially impacted by import tariffs with imports accounting for a low share of industry revenue.
The Traditional Chinese Medicine Manufacturing industry in China is unlikely to be materially impacted by export tariffs with exports accounting for a low share of industry revenue.
The market size of the Traditional Chinese Medicine Manufacturing industry in China has been growing at a CAGR of 8.0 % between 2020 and 2025.
Over the next five years, the Traditional Chinese Medicine Manufacturing industry in China is expected to grow.
The biggest companies operating in the Traditional Chinese Medicine Manufacturing industry in China are Beijing TongRenTang Co., Ltd., China Traditional Chinese Medicine Holdings Co., Ltd. and Kangmei Pharmaceutical Co., Ltd.
Herbal traditional Chinese medicine and Animal-based traditional Chinese medicine are part of the Traditional Chinese Medicine Manufacturing industry in China.
The company holding the most market share in the Traditional Chinese Medicine Manufacturing industry in China is Beijing TongRenTang Co., Ltd..
The level of competition is high and increasing in the Traditional Chinese Medicine Manufacturing industry in China.